⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL756341 | 1.00 | — | — | |
| SCHEMBL1650778 | 1.00 | — | — | |
| SCHEMBL17224577 | 0.98 | CYP2D6 (0.39) | — | |
| SCHEMBL6186602 | 0.82 | — | — | |
| SCHEMBL28763835 | 0.82 | — | — | |
| SCHEMBL890128 | 0.82 | — | — | |
| SCHEMBL890097 | 0.82 | — | — | |
| SCHEMBL1745137 | 0.80 | CYP2D6 (0.36) | — | |
| Lithium Ion SCHEMBL17224576 | 0.80 | — | — | |
| SCHEMBL1745139 | 0.80 | CYP2D6 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036557-A | Cycloserine intermediate and application thereof | 山东潍坊润丰化工股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20250326724-A1 | PROCESS FOR THE PREPARATION OF 4-SUBSTITUTED 2-OXAZOLIDINONES | SYNGENTA CROP PROTECTION AG (CH) | 2025-10-23 | — | — | US | disclosed |
| EP-4532475-A1 | PROCESS FOR THE PREPARATION OF 4-SUBSTITUTED 2-OXAZOLIDINONES | Syngenta Crop Protection AG (CH) | 2025-04-09 | — | — | EP | disclosed |
| CN-119301104-A | Process for preparing 4-substituted 2-oxazolidinones | 先正达农作物保护股份公司 | 2025-01-10 | — | — | CN | disclosed |
| WO-2023232560-A1 | PROCESS FOR THE PREPARATION OF 4-SUBSTITUTED 2-OXAZOLIDINONES | SYNGENTA CROP PROTECTION AG (CH) | 2023-12-07 | — | — | WO | disclosed |
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| CN-111808040-B | Synthesis method of multi-configuration 2-oxo-oxazolidine-4-carboxylic acid compounds | 苏州爱玛特生物科技有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-114031572-A | Process for preparing substituted cycloserines | 先正达参股股份有限公司 | 2022-02-11 | — | — | CN | disclosed |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20140206677-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2014-07-24 | — | — | US | disclosed |
| EP-1069132-B1 | Bicyclic derivatives of amino-pyrazinones, process of preparation and pharmaceutical compositions comprising them | SERVIER LAB (FR) | 2003-10-01 | — | — | EP | disclosed |
| EP-1147101-B1 | REVERSE HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LAB (US) | 2002-11-20 | — | — | EP | disclosed |
| EP-1147101-A1 | REVERSE HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6294573-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION | ABBOTT LABORATORIES | 2001-09-25 | — | — | US | disclosed |
| US-6277851-B1 | ORALLY ADMINISTERED TRYPSIN-RELATED SERINE PROTEASE INHIBITORS; ANTICOAGULANTS | ADIR ET COMPAGNIE (FR) | 2001-08-21 | — | — | US | disclosed |
| EP-1069132-A1 | Bicyclic derivatives of amino-pyrazinones, process of preparation and pharmaceutical compositions comprising them | ADIR ET COMPAGNIE (FR) | 2001-01-17 | — | — | EP | disclosed |
| WO-2000044739-A1 | REVERSE HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 2000-08-03 | — | — | WO | disclosed |
| US-5356918-A | Oxazolidinone compounds and method of using the same as a vasodilator | SANKYO COMPANY, LTD. (JP) | 1994-10-18 | — | — | US | disclosed |
| US-5298516-A | Treatment of cardiovascular disorders, angina | SANKYO COMPANY, LIMITED (JP) | 1994-03-29 | — | — | US | disclosed |